Acetyl-L-carnitine for alcohol craving and relapse prevention in anhedonic alcoholics: A randomized, double-blind, placebo-controlled pilot trial

Alcohol and Alcoholism

Volumn 45, Issue 5, 2010, Pages 449-455

  Martinotti, Giovanni ^a,b   Reina, Daniela ^b   di Nicola, Marco ^b   Andreoli, Sara ^a,b   Tedeschi, Daniela ^b   Ortolani, Ilaria ^b   Pozzi, Gino ^b   Iannoni, Emerenziana ^c   D'Iddio, Stefania ^c   Janiri, Luigi ^b  

^a Clinica Villa Maria Pia   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVACECARNINE; PLACEBO;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ACETYLCARNITINE; ADULT; ALCOHOLISM; BEHAVIOR, ADDICTIVE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; TEMPERANCE;

EID: 77956270246     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agq039     Document Type: Article

References (60)

1. Addolorato G, Leggio L, Abenavoli L et al. Alcoholism Treatment Study Group (2005) Neurobiochemical and clinical aspects of craving in alcohol addiction: a review. Addict Behav 30:209-24.
2. Anton RF, O'Malley SS, Ciraulo DA et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003-17.
3. Aureli T, Miccheli A, Ricciolini R et al. (1990) Aging brain: effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res 526:108-12.
4. Bella R, Biondi R, Raffaele R et al. (1990) Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res 10:355-60.
5. Blanken P, Hendriks V, Pozzi G et al. (1994) European Addiction Severity Index, EuropASI. A guide to training and administering EuropASI interviews. Bruxelles: European Cooperation in the Field of Scientific and Technical Research.
6. Bremer J. (1983) Carnitine-metabolism and functions. Physiol Rev 63:1420-80.
7. Burlina AP, Sershen H, Debler EA et al. (1989) Uptake of acetyl-Lcarnitine in the brain. Neurochem Res 14:489-93.
8. Calvani M, Carta A. (1992) Acetyl-L-carnitine: its role in neuronal metabolism. In Khachaturian ZS, Blass JP (eds). Alzheimer's Disease-New Treatment Strategies. New York: Marcel Dekker. 223-9.
9. Cardace G, Marzo A. (1993) Binding of L-Carnitine, Acetyl-L-Carnitine and Propionyl-L-Carnitine to: a) Plasma Proteins of Dogs and Humans; b) Albumin. Research Report No. 102-87, September 22.
10. Castorina M, Ferraris L. (1994) Acetyl-L-carnitine affects aged brain receptorial system in rodents. Life Sci 54:1205-14.
11. Chiechio S, Copani A, Gereau RW 4th et al. (2007) Acetyl-Lcarnitine in neuropathic pain: experimental data. CNS Drugs 21: 131-8; discussion 45-6.
12. De Grandis D. (2007) Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs 21:139-43; discussion 45-6.
13. De Simone C, Catania S, Trinchieri V et al. (1988) Ameliorating of the depression of HIV-infected subjects with L-acetyl-carnitine therapy. J Drug Dev 1:163-6.
14. Evans JD, Jacobs TF, Evans EW. (2008) Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 42:1686-91.
15. Falchetto S, Kato G, Provini L. (1971) The action of carnitines on cortical neurons. Can J Physiol Pharmacol 49:1-7.
16. First MB, Spitzer RL, Gibbon M et al. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute.
17. First MB, Spitzer RL, Gibbon M et al. (1990) Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). New York: Biometrics Research Department, New York State Psychiatric Institute.
18. Flannery BA, Roberts AJ, Cooney N et al. (2001) The role of craving in alcohol use, dependence, and treatment. Alcohol Clin Exp Res 25:299-308.
19. Fulgente T, Onorj M, Del Re ML et al. (1990) Laevo-acetylcarnitine treatment of senile depression. Clin Trials J 27:155-63.
20. Garzya G, Corallo D, Fiore A et al. (1990) Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 16:101-6.
21. Gass JT, Olive MF. (2008) Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75:218-65.
22. Gastfriend DR, Garbutt JC, Pettinati HM et al. (2007) Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat 33:71-80.
23. Gecele MG, Francesetti G, Meluzzi A. (1991) Acetyl-L-carnitine in aged subjects with major depression: clinical efficacy and effects on the circadian rhythm of cortisol. Dementia 2:333-7.
24. Gibson GE, Shimada M. (1980) Studies on the metabolic pathway of the acetyl group for acetylcholine synthesis. Biochem Pharmacol 29:167-74.
25. Guy W. (1976) ECDEU Assessment Manual for Psychopharmacology, Revised DHEW Publication No. (ADM). pp. 76-338.
26. Hudson S, Tabet N. (2003) Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev 2:CD003158.
27. Janiri L, Tempesta E. (1983) A pharmacological profile of the effects of carnitine and acetyl carnitine on the central nervous system. Int J Clin Pharmacol Res 3:295-306.
28. Janiri L, Falcone M, Persico A et al. (1991) Activity of L-carnitine and L-acetylcarnitine on cholinoceptive neocortical neurons of the rat in vivo. J Neural Transm Gen Sect 86:135-46.
29. Janiri L, Martinotti G, Dario T et al. (2005) Anhedonia and substance-related symptoms in detoxified substance-dependent subjects: a correlation study. Neuropsychobiology 52:37-44.
30. Janiri L, Martinotti G, Tonioni F et al. (2009) Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome. Clin Neuropharmacol 32:35-40.
31. Juliet PA, Balasubramaniam D, Balasubramaniam N et al. (2003) Carnitine: a neuromodulator in aged rats. J Gerontol A Biol Sci Med Sci 58:970-4.
32. Kenna GA, McGeary JE, Swift RM. (2004a) Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. Am J Health Syst Pharm 61:2272-9.
33. Kenna GA, McGeary JE, Swift RM. (2004b) Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am J Health Syst Pharm 61:2380-8.
34. Kido Y, Tamai I, Ohnari A et al. (2001) Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 79:959-69.
35. Leggio L. (2009) Understanding and treating alcohol craving and dependence: recent pharmacological and neuroendocrinological findings. Alcohol Alcohol 44:341-52.
36. Lejoyeux M, Solomon J, Ades J. (1998) Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 33:563-75.
37. Lin N, Hubbard JI. (1995) An NMDA receptor antagonist reduces ethanol preference in untrained but not trained rats. Brain Res Bull 36:421-4.
38. Liraud F, Verdoux H. (2001) Association between temperamental characteristics and medication adherence in subjects presenting with psychotic or mood disorders. Psychiatry Res 102:91-5.
39. Mancinelli A, Longo A, Shanahan K et al. (1995) Disposition of Lcarnitine and acetyl-L-carnitine in the isolated perfused rat kidney. J Pharmacol Exp Ther 274:1122-8.
40. Martinotti G, Di Nicola M, Di Giannantonio M et al. (2009) Aripiprazole in the treatment of patients with alcohol dependence: a doubleblind, comparison trial vs. naltrexone. J Psychopharmacol 23: 123-9.
41. Marzo A, Arrigoni Martelli E, Urso R et al. (1989) Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteers. Eur J Clin Pharmacol 37:59-63.
42. Mottola CA. (1993) Measurement strategies: the visual analogue scale. Decubitus 6:56-8.
43. Nakamura J, Koh N, Sakakibara F et al. (1998) Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats. J Pharmacol Exp Ther 287:897-902.
44. Nasca D, Zurria G, Aguglia E. (1989) Action of acetyl-L-carnitine in association with mianserine on depressed people. New Trends Clin Neuropharmacol 3:225-30.
45. Parnetti L, Gaiti A, Mecocci P et al. (1992) Pharmacokinetics of i.v. and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur J Clin Pharmacol 42:89-93.
46. Pettegrew JW, Levine J, Gershon S et al. (2002) 31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results. Bipolar Disord 4:61-6.
47. Rossini M, Di Munno O, Valentini G et al. (2007) Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 25: 182-8.
48. Ruggenenti P, Cattaneo D, Loriga G et al. (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk. Effects of acetyl-L-carnitine therapy. Hypertension 54:567-74.
49. Scheggi S, Rauggi R, Nanni G et al. (2004) Repeated acetyl-l-carnitine administration increases phospho-Thr34 DARPP-32 levels and antagonizes cocaine-induced increase in Cdk5 and phospho-Thr75 DARPP-32 levels in rat striatum. Eur J Neurosci 19:1609-20.
50. Sima AA. (2007) Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 21:13-23; discussion 45-46.
51. Snaith RP, Hamilton M, Morley S et al. (1995) A scale for the assessment of hedonic tone. The Snaith Hamilton Pleasure Scale. Br J Psychiatry 167:99-103.
52. Sullivan JT, Sykora K, Schneiderman J et al. (1989) Assessment of alcohol withdrawal: the revised clinical Institute Withdrawal Assessment for Alcohol scale (CIWA Ar). Br J Addict 84:353-7.
53. Tempesta E, Casella L, Pirrongelli C et al. (1987) L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 13:417-23.
54. Villa RF, Gorini A. (1991) Action of L-acetylcarnitine on different cerebral mitochondrial populations from hippocampus and striatum during aging. Neurochem Res 16:1125-32.
55. Villardita C, Smirni P, Vecchio I. (1984) L-Acetylcarnitine in depressed elderly patients. Eur Rev Med Pharmacol Sci 62:341-4.
56. Virmani A, Gaetani F, Imam S et al. (2002) The protective role of Lcarnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction. Ann N Y Acad Sci 965:225-32.
57. Volpicelli LA, Lah JJ, Fang G et al. (2002) Rab11a and myosin Vb regulate recycling of the M4 muscarinic acetylcholine receptor. J Neurosci 22:9776-84.
58. Wang J, Carnicella S, PhamluongKet al. (2007) Ethanol induces longterm facilitation of NR2B-NMDA receptor activity in the dorsal striatum: implications for alcohol drinking behavior. J Neurosci 27:3593-602.
59. White HL, Scates PW. (1990) Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res 15:597-601.
60. Zanardi R, Smeraldi E. (2006) A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 16:281-7.